Anders Koch has been appointed as the new CFO for Prostatype Genomics and takes up the position with immediate effect. Anders' extensive experience in streamlining and optimizing operations during growth on an international level will be a great asset for Prostatype Genomics. Anders Koch has over 25 years of experience from positions in finance and leadership, most recently from an interim assignment at Goodbye Kansas Group AB (publ), also listed on Nasdaq First North.

Anders Koch succeeds Michael af Winklerfelt, who remains in the company during a handover period.